SecBot SecBot
6-K ·Filed Jul 13, 2026

GSK

GSK plc
NEUTRAL
Impact 1/10
Horizonimmediate Processed4mo ago SEC0001654954-26-006623
Notable filing: 6-K
Actionable Insight • Neutral

No trading signal. This is a routine compliance filing for share plan and dividend reinvestment. Monitor next quarterly results (2.02) or any material 8-K for actionable events.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$52.29
T+0 close · Jul 13, 2026 · via day close
Latest settled
−10.88%
T+60 · $46.60
Vs SPY
−14.88%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 13 $52.29entry
  2. T+1 · 4mo ago −1.99%α −2.34% · $51.25
  3. T+5 · 4mo ago −1.01%α −0.23% · $51.76
  4. T+20 · 3mo ago −0.25%α −3.43% · $52.16
  5. T+60 · 6w ago −10.88%α −14.88% · $46.60
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK filed a routine 6-K reporting PDMR share acquisitions under the company's Share Reward Plan and dividend reinvestment on July 9, 2026. Multiple executives including the CEO, CFO, and other senior leaders acquired small numbers of ordinary shares at ~£19.63, with the largest single purchase being 1,050 shares by a PCA of the Company Secretary. This is a standard administrative disclosure with no material financial or strategic implications.

Key Facts

  • CEO Luke Miels acquired 3 ordinary shares via dividend reinvestment at £19.6290.
  • CFO Julie Brown acquired 12 ordinary shares (6 partnership + 6 matching) under the Share Reward Plan at £19.6290.
  • Largest single transaction: Iain Whyte (PCA of SVP & Company Secretary) acquired 1,050 shares via dividend reinvestment at £19.6297.
  • All transactions occurred on July 9, 2026 on the London Stock Exchange.
  • Total aggregate value of all reported transactions is approximately £23,000 (based on ~1,170 shares at ~£19.63).

Financial Impact

Negligible, total transaction value ~£23,000 against a $106.9B market cap.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
43% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-006623
Document: 0001654954-26-006623-index-headers.html0001654954-26-006623
Document: 0001654954-26-006623-index.html0001654954-26-006623
Document: 0001654954-26-006623.txt0001654954-26-006623

US Market Status

Market Closed · Opens Wed (10h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026